Leukemic Stem Cell (CD34/CD38/TIM3) Frequency in Patients with Acute Myeloid Leukemia: Clinical Implications.

This study aimed to address the prognostic relevance of CD34/CD38/TIM3 leukemic stem cell (LSC) frequency in patients with acute myeloid leukemia (AML) and its impact on patient outcome. We analyzed the expression of LSC markers (CD34/CD38/TIM3) using flow cytometry in bone marrow samples of 53 AML cases before and after induction chemotherapy. The LSC frequency at diagnosis was significantly higher compared with that postinduction (P < .